News | Proton Therapy | October 28, 2016

IBA Reaches 50,000 Patients Treated with Proton Therapy Systems

With the number of treated patients growing by over 20 percent year by year, patient access will double by 2020, according to the company

IBA, proton therapy, 50,000 patients treated, milestone

October 27, 2016 — IBA announced in September that 50,000 patients have been treated by clinical partners using IBA’s proton therapy technology.

Today, on average, one new patient is treated every hour on IBA systems around the globe, according to Yves Jongen, chief research officer and founder of IBA. The company’s mission, Jongen said, is to make proton therapy available to an estimated 20 percent of radiation patients that could benefit from this type of treatment.

More and more clinical opinion leaders are working on collecting and producing evidence confirming the added value of proton therapy. This addresses not only comparative clinical outcome, but also economic effectiveness of the total treatment. Proton therapy is offering new hope for patients with specific brain, eye, lung and head and neck cancers, due to their very sensitive locations in the body, where it is imperative to preserve surrounding healthy tissue. Most importantly, proton therapy has emerged as a preferred treatment option for pediatric cases, according to IBA, where the damage done to the still growing tissues and organs of children is often irreversible.

This is the reason why IBA said it is investing between 12-15 percent of its revenue in research and development (R&D) — currently the largest share in the sector. One of the outcomes of IBA’s R&D was the ProteusOne proton therapy solution. This is the most compact proton therapy system ever designed, according to the company, which is easier to implement, operate and finance.

IBA said the future of proton therapy is even more encouraging in the light of the advent of adaptive proton therapy (adaPT), widely considered as the next breakthrough in the field. Adaptive workflows, as modular proton therapy processes, add yet another layer of accuracy in what many consider the most precise and least intrusive cancer treatment method. IBA recently created an international online Community platform,, to enable experts in the field from all over the world to exchange experiences, discuss best practices and enhance knowledge, to improve the next generation of proton therapy treatment.

For more information:

Related Content

Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Videos | Treatment Planning | August 28, 2018
A discussion with...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...
Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and